{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:18:26Z","timestamp":1772119106568,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore patients\u2019 perceptions of managing adverse events (AEs) from anticancer drugs for gynaecological cancer, focusing on AEs they want to avoid, views on dose adjustments and communication with healthcare professionals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Observational study using a web-based questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Women in Japan who had received chemotherapy for endometrial or ovarian\/fallopian tube cancer were enrolled. Healthcare professionals, including obstetrics and gynaecology physicians, nurses and pharmacists, who administered chemotherapy to these patients, were also enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>AEs that patients wished to avoid or found distressing; varied perceptions of AEs before and after treatment; discrepancies in the communication of AEs between patients and healthcare professionals; administration time and intervals between hospital visits patients found distressing; patient awareness of dose adjustment (reduction, interruption or discontinuation) to suppress AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants comprised 153 physicians, 166 nurses, 154 pharmacists and 154 patients. Nausea\/vomiting (28.6%), alopecia (18.2%) and peripheral neuropathy (9.1%) were the most distressing AEs overall. Physicians rated nausea\/vomiting lower (15.4%) and alopecia higher (38.2%) than patients, while pharmacists emphasised peripheral neuropathy (25.7%). Many patients found AEs, including peripheral neuropathy (53\/99), fatigue (52\/105) and alopecia (46\/120), to be more severe than expected. Communication patterns revealed that 49.4% of patients reported all symptoms, even uncertain ones, but younger patients tended to communicate fewer symptoms. Physicians (54.2%), nurses (92.2%) and pharmacists (85.7%) preferred full disclosure of symptoms. While 28.6% of patients wished to avoid dose reductions because of fears of disease progression, 18.2% preferred dose reduction or discontinuation when AEs became intolerable. Drug administration times and visit intervals influenced patient distress. Treatment administration of over 3\u2009hours (19.5%) and visits occurring more frequently than once every 3 weeks (27.3%) were the most distressing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights discrepancies in AE perceptions and communication between patients and healthcare professionals, emphasising the need for tailored communication strategies and shared decision-making to improve cancer treatment experiences and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCT1040220088, Japan Registry of Clinical Trials (jRCT).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107743","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:25Z","timestamp":1772115325000},"page":"e107743","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Disparities in adverse event perception between patients and healthcare providers in gynaecologic anticancer therapy: results from an observational web-based study in Japan"],"prefix":"10.1136","volume":"16","author":[{"given":"Hironobu","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Soejima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Nursing, The Hospital of Hyogo College of Medicine, Nishinomiya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Ike","sequence":"additional","affiliation":[{"name":"Eisai Co Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Eisai Co Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tohoku University Hospital, Sendai, Japan"},{"name":"Department of Clinical Biobank, Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8508-3997","authenticated-orcid":false,"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026022606151472000_16.2.e107743.1","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1200\/JCO.2017.35.15_suppl.5503","article-title":"A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043)","volume":"35","author":"Nomura","year":"2017","journal-title":"JCO"},{"key":"2026022606151472000_16.2.e107743.2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol Oncol"},{"key":"2026022606151472000_16.2.e107743.3","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-002230"},{"key":"2026022606151472000_16.2.e107743.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.014"},{"key":"2026022606151472000_16.2.e107743.5","article-title":"Adjuvant chemotherapy for advanced endometrial cancer","volume":"2014","author":"Galaal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022606151472000_16.2.e107743.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00334-6"},{"key":"2026022606151472000_16.2.e107743.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"2026022606151472000_16.2.e107743.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132"},{"key":"2026022606151472000_16.2.e107743.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"2026022606151472000_16.2.e107743.10","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.3390\/curroncol29040231","article-title":"New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review","volume":"29","author":"Gheorghe","year":"2022","journal-title":"Curr Oncol"},{"key":"2026022606151472000_16.2.e107743.11","doi-asserted-by":"crossref","first-page":"103851","DOI":"10.1016\/j.critrevonc.2022.103851","article-title":"Advanced and recurrent endometrial cancer: State of the art and future perspectives","volume":"180","author":"Tronconi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026022606151472000_16.2.e107743.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0911494"},{"key":"2026022606151472000_16.2.e107743.13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.trecan.2023.01.006","article-title":"The unequal burden of time toxicity","volume":"9","author":"Johnson","year":"2023","journal-title":"Trends Cancer"},{"key":"2026022606151472000_16.2.e107743.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026022606151472000_16.2.e107743.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01076"},{"key":"2026022606151472000_16.2.e107743.16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","article-title":"Management of treatment-related toxicity in advanced ovarian cancer","volume":"7 Suppl 5","author":"Dunton","year":"2002","journal-title":"Oncologist"},{"key":"2026022606151472000_16.2.e107743.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.088"},{"key":"2026022606151472000_16.2.e107743.18","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15618131"},{"key":"2026022606151472000_16.2.e107743.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"2026022606151472000_16.2.e107743.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"2026022606151472000_16.2.e107743.21","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.21832.1","article-title":"Management strategies for the treatment and prevention of postoperative\/postdischarge nausea and vomiting: an updated review","volume":"9","author":"Elvir-Lazo","year":"2020","journal-title":"F1000Res"},{"key":"2026022606151472000_16.2.e107743.22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.35772\/ghm.2022.01062","article-title":"Distress and impacts on daily life from appearance changes due to cancer treatment: A survey of 1,034 patients in Japan","volume":"5","author":"Nozawa","year":"2023","journal-title":"Glob Health Med"},{"key":"2026022606151472000_16.2.e107743.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102831"},{"key":"2026022606151472000_16.2.e107743.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030373","article-title":"Cancer-Related Neuropathic Pain","volume":"11","author":"Edwards","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026022606151472000_16.2.e107743.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00168-y"},{"key":"2026022606151472000_16.2.e107743.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.09.016"},{"key":"2026022606151472000_16.2.e107743.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjon.2023.100198","article-title":"Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study","volume":"10","author":"Kanda","year":"2023","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026022606151472000_16.2.e107743.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40780-022-00239-w","article-title":"Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy","volume":"8","author":"Fujii","year":"2022","journal-title":"J Pharm Health Care Sci"},{"key":"2026022606151472000_16.2.e107743.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40780-024-00403-4","article-title":"Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes","volume":"10","author":"Fujii","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"2026022606151472000_16.2.e107743.30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219833441"},{"key":"2026022606151472000_16.2.e107743.31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.910722","article-title":"The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1\/PD-L1 inhibitors","volume":"13","author":"Kou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026022606151472000_16.2.e107743.32","unstructured":"International Pharmaceutical Federation (IPF) . Cancer care: A handbook for pharmacists, Available: https:\/\/www.fip.org\/file\/5248"},{"key":"2026022606151472000_16.2.e107743.33","unstructured":"Ministry of Health, Labour and Welfare . Survey on the number of physicians required, Available: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryou\/hitsuyouishisuu\/index.html"},{"key":"2026022606151472000_16.2.e107743.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09863-0","article-title":"A scoping review on the factors associated with the lost to follow-up (LTFU) amongst patients with chronic disease in ambulatory care of high-income countries (HIC)","volume":"23","author":"Tong","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"2026022606151472000_16.2.e107743.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.6.756"},{"key":"2026022606151472000_16.2.e107743.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00776-9"},{"key":"2026022606151472000_16.2.e107743.37","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2217\/fon-2023-0335","article-title":"Actual situation of decision-making support from medical staff when cancer patients make treatment choices","volume":"19","author":"Kawasaki","year":"2023","journal-title":"Future Oncol"},{"key":"2026022606151472000_16.2.e107743.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"},{"key":"2026022606151472000_16.2.e107743.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05029-z"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:28Z","timestamp":1772115328000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-107743"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107743","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}